| dc.creator |
Turkvatan, Aysel |
|
| dc.creator |
Balci, Mustafa |
|
| dc.creator |
Kirkpantur, Alper |
|
| dc.creator |
Afsar, Barış |
|
| dc.date |
2016-01-01T01:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:30:30Z |
|
| dc.date.available |
2021-12-03T11:30:30Z |
|
| dc.identifier |
72beeebd-6b1a-471c-a1a9-d4a02e09f6bb |
|
| dc.identifier |
10.1016/j.nefro.2015.07.006 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/72beeebd-6b1a-471c-a1a9-d4a02e09f6bb/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/92550 |
|
| dc.description |
Background: Bone and mineral abnormalities, and cardiovascular calcification are associated with increased cardiovascular mortality in patients with chronic kidney disease (CKD). Recent studies have implicated Wnt signaling pathway in the pathogenesis of bone metabolism and vascular calcification. Sclerostin is a soluble inhibitor of Wnt signaling pathway and has been shown to be associated with decreased bone tumover and vascular calcification in CKD patients. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients |
|
| dc.type |
info:eu-repo/semantics/article |
|